Bristol-Myers Squibb
BMS makes record $1.8bn bet on Nektar cancer drug
Bristol-Myers Squibb, cancer, cancer immunotherapy, Merck & Co, Nektar Therapeutics, R&D
0 Comment
Clovis and BMS combine cancer drugs in late-stage trials
BMS, cancer, Clovis, immunotherapy, Opdivo
0 Comment
Clovis and BMS research small molecule and antibody combination.
BMS appoints new science chief in fall-out from Opdivo setback
Bristol-Myers Squibb, cancer, cancer immunotherapy, Merck & Co, R&D
0 Comment
Is BMS the next pharma takeover target?
Bristol-Myers Squibb, cancer, cancer immunotherapy, Gilead, M&A, Novartis, Pfizer
0 Comment
Speculation mounting that Pfizer and others could try for $90 bn plus merger
Innate and BMS’ immunotherapy fails in phase 2 trial
Bristol-Myers Squibb, cancer, cancer immunotherapy, Innate Pharma, R&D
0 Comment
French biotech developing cancer immunotherapy with BMS.
BMS suffers further setback in lung cancer
Bristol-Myers Squibb, cancer, cancer immunortherapy, lung cancer, Merck & Co, Oncology, R&D
0 Comment
No fast approval for immunotherapy combo in first line use.
Novartis, BMS, Janssen unveil R&D deals
Biogen, Biotech, Bristol-Myers Squibb, cancer, cardiology, Ionis Pharmaceuticals, Janssen, Johnson & Johnson, JP Morgan healthcare conference, Novartis, US biotech
0 Comment
Companies announce eye-catching R&D plans ahead of conference.